Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
DUBLIN, April 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 first quarter financial results on Wednesday, May 1, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2024 first quarter financial results and provide a business and financial update.
都柏林，2024年4月17日 /PRNewswire/ — Jazz Pharmicals plc（納斯達克股票代碼：JAZZ）今天宣佈，將在美國金融市場收盤後於2024年5月1日星期三公佈其2024年第一季度財務業績。公司管理層將在美國東部時間下午 4:30 /美國東部標準時間晚上 9:30 主持網絡直播，討論2024年第一季度財務業績並提供業務和財務最新情況。
Audio webcast/conference call:
U.S. Dial-In Number: +1 800 715 9871
Ireland Dial-In Number: +353 1800 943 926
Additional global dial-in numbers are available here.
Passcode: 8991966
音頻網絡直播/電話會議：
美國撥入號碼：+1 800 715 9871
愛爾蘭撥入號碼：+353 1800 943 926
其他全球撥入號碼可在此處獲取。
密碼：8991966
Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
有興趣的人士可以通過Jazz Pharmicals網站的 “投資者” 部分訪問網絡直播爲了確保及時連接，建議參與者至少在預定的網絡直播前15分鐘註冊。
A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at
網絡直播的重播將通過Jazz Pharmicals網站的 “投資者” 欄目播出，網址爲
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit for more information.
關於爵士製藥
Jazz Pharmaceuticals plc（納斯達克股票代碼：JAZZ）是一家全球生物製藥公司，其宗旨是通過創新來改變患者及其家屬的生活。我們致力於爲患有嚴重疾病的人開發改變生活的藥物——通常治療選擇有限或根本沒有。我們擁有多樣化的上市藥物組合，包括領先的睡眠障礙和癲癇療法，以及不斷增長的癌症治療產品組合。我們以患者爲中心、以科學爲導向的方法爲我們在腫瘤學和神經科學領域強大的創新療法產品線中取得開創性的研發進展提供了動力。Jazz 總部位於愛爾蘭都柏林，在多個國家設有研發實驗室、製造設施和員工，致力於爲全球患者提供服務。請訪問以獲取更多信息。
Investors:
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
[email protected]
Ireland +353 1 634 3211
U.S. +1 650 496 2717
投資者：
安德里亞·弗林博士
副總裁、投資者關係主管
爵士製藥有限公司
[電子郵件保護]
愛爾蘭 +353 1 634 3211
美國 +1 650 496 2717
Media Contact:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
[email protected]
Ireland +353 1 637 2141
U.S. +1 215 867 4948
媒體聯繫人：
克里斯汀·巴夫納尼
全球企業傳播主管
爵士製藥有限公司
[電子郵件保護]
愛爾蘭 +353 1 637 2141
美國 +1 215 867 4948
SOURCE Jazz Pharmaceuticals plc
來源 Jazz 製藥有限公司
譯文內容由第三人軟體翻譯。